Overview
No overview information available.
Indication
No indication information available.
Associated Conditions
- Acquired hemolytic anemias
- Acute Gouty Arthritis
- Ankylosing Spondylitis (AS)
- Berylliosis
- Bullous dermatitis herpetiformis
- Congenital Adrenal Hyperplasia (CAH)
- Congenital Hypoplastic Anemia
- Dermatomyositis (DM)
- Edema of the cerebrum
- Hypercalcemia
- Idiopathic Nephrotic Syndrome
- Immune Thrombocytopenia (ITP)
- Leukemias
- Lymphoma
- Mycosis Fungoides (MF)
- Ocular Inflammatory Disease
- Ophthalmia, Sympathetic
- Pemphigus
- Polymyositis
- Primary adrenocortical insufficiency
- Proteinuria
- Psoriatic Arthritis
- Pure Red Cell Aplasia
- Regional Enteritis
- Rheumatoid Arthritis
- Rheumatoid Arthritis, Juvenile
- Secondary adrenocortical insufficiency
- Secondary thrombocytopenia
- Stevens-Johnson Syndrome
- Systemic Lupus Erythematosus
- Temporal Arteritis
- Trichinosis
- Tuberculous Meningitis
- Ulcerative Colitis
- Uveitis
- Acute rheumatic carditis
- Disseminated Pulmonary Tuberculosis (TB)
- Exfoliative erythroderma
- Fulminating Pulmonary Tuberculosis
- Idiopathic eosinophilic pneumonias
- Severe Allergic Reactions
- Severe Erythema multiforme
- Symptomatic Sarcoidosis
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/02/08 | Phase 1 | Recruiting | |||
2023/03/09 | Phase 2 | Recruiting | |||
2022/09/09 | Phase 2 | Recruiting | |||
2022/04/27 | Phase 4 | UNKNOWN | The London Clinic | ||
2022/04/11 | Phase 1 | Withdrawn | |||
2020/09/14 | Phase 2 | Recruiting | |||
2020/03/10 | Phase 3 | UNKNOWN | |||
2017/04/12 | Phase 4 | UNKNOWN | Xijing Hospital of Digestive Diseases | ||
2016/08/30 | Phase 3 | Active, not recruiting | |||
2016/07/11 | Phase 2 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| HF Acquisition Co. LLC, DBA HealthFirst | 51662-1262 | INTRAMUSCULAR, INTRAVENOUS | 250 mg in 2 mL | 2/22/2024 | |
| Cardinal Health 107, LLC | 55154-3942 | INTRAMUSCULAR, INTRAVENOUS | 100 mg in 2 mL | 10/17/2018 | |
| HF Acquisition Co. LLC, DBA HealthFirst | 51662-1261 | INTRAMUSCULAR, INTRAVENOUS | 100 mg in 2 mL | 2/22/2024 | |
| Pharmacia & Upjohn Company LLC | 0009-0013 | INTRAMUSCULAR, INTRAVENOUS | 250 mg in 2 mL | 1/4/2024 | |
| Pharmacia & Upjohn Company LLC | 0009-0005 | INTRAMUSCULAR, INTRAVENOUS | 1000 mg in 8 mL | 1/4/2024 | |
| Pharmacia & Upjohn Company LLC | 0009-0016 | INTRAMUSCULAR, INTRAVENOUS | 500 mg in 4 mL | 1/4/2024 | |
| Pharmacia & Upjohn Company LLC | 0009-0825 | INTRAMUSCULAR, INTRAVENOUS | 100 mg in 2 mL | 1/4/2024 | |
| Pharmacia & Upjohn Company LLC | 0009-0011 | INTRAMUSCULAR, INTRAVENOUS | 100 mg in 2 mL | 1/4/2024 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| SOLU-CORTEF FOR INJECTION 100 mg/vial | SIN04791P | INJECTION, POWDER, FOR SOLUTION | 100 mg/vial | 6/26/1990 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Help Us Improve
Your feedback helps us provide better drug information and insights.